

CORRESPONDENCE

Open Access

Structural basis for neutralization of an anicteric hepatitis associated echovirus by a potent neutralizing antibody

Rui Feng^{1,2}, Lei Wang^{1,2}, Dawei Shi³, Binyang Zheng⁴, Li Zhang⁴, Hai Hou⁵, Deju Xia³, Lunbiao Cui⁴, Xiangxi Wang^{1,2}, Sihong Xu³, Kang Wang¹ and Ling Zhu¹

Dear Editor,

Human enteroviruses (HEVs) are ubiquitous pathogens responsible for multiple human diseases, ranging from hand-foot-and-mouth disease (HFMD), meningitis, to poliomyelitis, encephalitis, etc¹. HEVs comprise four main groups, Enterovirus A–D (HEV-A, B, C, and D), among which HEV-B is the largest group, including coxsackievirus A9 (CVA9), coxsackievirus B1–6 (CVB1–6), and over 30 serotypes of echoviruses. Echovirus 3 (E3), a serotype of HEV-B, first isolated in 1953, leads to highly contagious and severe diseases in humans, such as aseptic meningitis, myocarditis, and anicteric hepatitis². Infection in neonates and infants within the first few weeks of life can be fatal. Currently, there are no approved vaccines or antiviral drugs for treating infections caused by viruses belonging to the HEV-B group.

Although the atomic structures for numerous HEVs have been studied^{3–8}, large gaps in our knowledge concerning structural determinants for specificity between the serotypes/subgroups and immunogenic characteristics for serotype-specific or cross-reactive epitopes within HEV-Bs still exist. Therefore, an in-depth understanding of the structural, immunogenic features and key epitopes of E3 should be useful in providing guidance for the rational drug design against HEV-B infections. We obtained the E3 virus (genotype HNWX-01 strain) from

the Jiangsu Provincial Center for Disease Control and Prevention (CDC) and propagated it in RD cells. Following rounds of purifications and analyses, three types of particles were identified, one containing significant amounts of viral RNA characterized as mature virus (or full particle, F-particle) and the other two being empty inside with substantially different sizes defined as expanded and compact empty particles (EE- and EC-particles) (Supplementary Fig. S1). Cryo-electron microscopic (cryo-EM) structures of the three types of particles: F-particle (~64%), EC-particle (~3%), and EE-particle (~33%) were reconstructed to 3.2 Å, 3.8 Å, and 3.1 Å resolution, respectively (Fig. 1a; Supplementary Figs. S2a and S3a–c and Table S1). The external surfaces of the F- and EC-particles with a diameter of ~325 Å are indistinguishable, apart from some disorder on the inside of the EC-particle, including N-termini of VP1 and VP0 (Fig. 1a). By contrast, the EE-particle exhibits a typical expanded form with a ~4.5% increase in diameter (~340 Å) and notable perforations at the icosahedral two-fold axes (Fig. 1a; Supplementary Figs. S4 and S5d). Superimposition of the asymmetric units (protomers) verifies the similarity in capsid structures of the F- and EC-particles and reveals substantial conformational differences between F- and EE-particles in several exposed loops, such as VP1 BC, DE, EF and HI loops, VP3 EF and GH loops (Supplementary Figs. S4 and S5a–c). Remarkably, most of these loops are key determinants for immunogenicity in HEVs, indicating that EC-particle, rather than EE-particle, has more potential as candidates for the development of a vaccine. Incorporation of EE-particles in the vaccine would require a rational strategy to facilitate the structural transition from the expanded to the compact state.


Correspondence: Xiangxi Wang (xiangxi@ibp.ac.cn) or Sihong Xu (xushong@nifdc.org.cn) or Kang Wang (wangkangup@163.com) or Ling Zhu (lingzhu@ibp.ac.cn)


¹CAS Key Laboratory of Infection and Immunity, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China

²University of Chinese Academy of Sciences, Beijing 100049, China

Full list of author information is available at the end of the article
These authors contributed equally: Rui Feng, Lei Wang, Dawei Shi

© The Author(s) 2021

 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.



A structure-based phylogenetic tree constructed from the biological protomers indicates four main subgroups within HEV-Bs, among which E3, together with E6 and E30 constitutes one subgroup, lying almost equidistant from the CVBs, E18, and CVA9-representative subgroups (Fig. 1b). Although the overall structures of these HEV-Bs resemble each other, major structural features distinguishing the subgroups lie in the plateaus (also named as “mesa”) surrounding the five-fold axes (Fig. 1b). Compared with the representative HEV-Bs from the other three subgroups, E3 exhibits dense “pentagon-shaped” protrusions, while CVBs and CVA9 harbor five prominent spiraling and five discontinuous protrusions, respectively (Fig. 1c). Intriguingly, E18 is remarkably smaller with a diameter of 314 Å, differing radically from that of other HEV-Bs (~325 Å) (Fig. 1c). These structural variations arise from the altered conformations of several loops located at the five-fold axes, such as VP1 BC, DE, and HI loops (Fig. 1d). A number of key structural elements, including the VP1 BC, DE loops and C-terminus, the VP2 EF loop and VP3 EF, GH loops, contribute to the serotype-specific antigenic sites and construct the “canyon”, where many HEV receptors often bind (Fig. 1c, d; Supplementary Fig. S4)^{1,3}. Notably, VP1 C-terminus, appearing to be the most divergent in sequence among the four subgroups in HEV-Bs (Supplementary Fig. S4), is largely disordered in the native virus structures (F-, EC-, and EE-particles), indicative of a cryptic immunogenic site, akin to the VP1 GH loop in foot-and-mouth disease virus (FMDV)⁹.

To elucidate the immunogenic characteristics of E3 F-particles, sixteen monoclonal antibodies were generated by immunizing mice. Of these, the one named 5G3, exhibited tight binding to E3 with a K_D of 0.25 nM as determined by surface plasmon resonance (SPR) and potent neutralizing activity against E3 (a 50% neutralizing concentration ($Neut_{50}$) value of ~0.3 nM) (Fig. 1e, f). To decipher the bona fide epitopes on E3 targeted by 5G3, we determined the cryo-EM structures of 5G3 in complex with E3 F- and EE-particles at 3.9 Å and 4.1 Å, respectively (Fig. 1g; Supplementary Figs. S2b, c and S3d, e and Table S2). The overall structures of two immune complexes reveal the identical epitope and binding pattern. The higher resolution structure of E3 F-particle-5G3 was used to analyze the detailed virus-antibody interactions. 5G3 binds to the viral surface along the edges of the pentameric building blocks of the virus adjacent to two-fold axes in a similar position to that observed for R10 antibody bound to hepatitis A virus (Fig. 1h)¹⁰. The light chain and heavy chain variable domains contribute ~64.2% and ~35.8% of the protein-protein interactions, respectively, with the light chain predominantly binding VP1 (Fig. 1i). The 5G3 paratope comprises three complementary determining regions (CDRs): L1 (residues

31–33), L3 (residues 98 and 100), and H2 (residues 51 and 54). The 5G3 epitope contains residues 283–287 and 292 in VP1 C-terminus as well as residues 140 and 143 in VP3. Disordered in the apo structure, VP1 C-terminus (residues 275–292) in the complex structure, however, inserts into a highly hydrophobic cleft constructed by LCDR1, LCDR3, and HCDR2 (Fig. 1i, upper left panel and upper right panel). These hydrophobic interactions thereby dominate the virus-antibody recognition and this tight binding are further facilitated by a number of hydrogen bonds (Fig. 1i, lower left panel and lower right panel). Notably, none of the residues comprising the epitopes are conserved (0/7) across HEV-Bs (Supplementary Figs. S4 and S6), suggesting that 5G3 is a serotype-specific neutralizing antibody. In line with many other HEV-Bs, E3 utilizes CD55 for viral attachment and FcRn for viral uncoating, gaining efficient entry into the host cells¹¹. To dissect the neutralization mechanism of 5G3, we generated the footprint of this antibody on the E3 surface and discovered that it did not overlap with the viral receptor-binding sites (CD55 and FcRn) (Supplementary Fig. S7). However, superimposition of the structures of E30-FcRn (PDB:7C9V) or E30-CD55 (PDB:7C9W) over E3-5G3 revealed steric clashes between the two receptors and 5G3 (Fig. 1j). Therefore, 5G3 could potentially neutralize E3 infection via blocking the interactions with its two receptors.

In summary, the atomic structures of E3 mature virion and the two types of empty particles reveal serotype-specific structural features between the subgroups within HEV-Bs and underline the potential of E3 F- or EC-particles as ideal vaccine candidates. The immunogenic characteristics and bona fide epitopes defined by the first E3-neutralizing antibody 5G3 underpin the immunogenic differences in EV-B, informing strategies for vaccine and therapeutics design against this anicteric hepatitis associated echovirus.

Acknowledgements

We thank B. Zhu, X. Huang, X. Li, and G. Ji for Cryo-EM data collection at the Center for Biological Imaging (CBI), Institute of Biophysics. We also thank Y. Chen, Z. Yang, and B. Zhou for SPR technical support and X. Yu for AUC technical guidance. This work was supported by the Strategic Priority Research Program (XDB29010000 and XDB37030201), Beijing Natural Science Foundation-Haidian Primitive Innovation Joint Fund (L192008), the Key Programs of the Chinese Academy (KJZD-SW-L05), the National Key R&D Program (2018YFA0900801 and 2017YFC0840300), the National Science Foundation of China (31800145, 31941011, 31900873, and 81520108019) and Center for Biosafety Mega-Science, CAS and Applied Technology Research and Development Project of Heilongjiang Province (GA19B301). Ling Zhu was supported by the Youth Innovation Promotion Association at the Chinese Academy of Sciences (2019098).

Author details

¹CAS Key Laboratory of Infection and Immunity, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. ²University of Chinese Academy of Sciences, Beijing 100049, China. ³Institute for In Vitro Diagnostics Control, National Institutes for Food and Drug Control, Beijing 100050, China. ⁴National Health Commission of

the People's Republic of China, Key laboratory of Enteric Pathogenic Microbiology (Jiangsu Provincial Center for Disease Control and Prevention), Nanjing 210009 Jiangsu, China. ⁵Institute of Medical Research, Northwestern Polytechnical University, Xi'an 710072 Shaanxi, China

Author contributions

R.F., L.W., K.W., D.S., and B.Z. performed the experiments. K.W. and L.W. solved the structure, L.Z., L.C., D.X., and H.H. provided reagents. L.Z., K.W., S.X., and X.W. designed the study. All authors analyzed the data. L.Z., X.W., and K.W. wrote the paper.

Data availability

The atomic coordinates of E3 F-, EC- and EE-particles as well as E3 (F-particle)-, E3 (EE-particle)-5G3 complexes have been submitted to the Protein Data Bank with accession numbers: 7C9X, 7EAI, 7EAH, 7EAK, and 7EAJ, respectively. Their corresponding cryo-EM maps have been deposited in the Electron Microscopy Data Bank under accession codes: EMD-30320, EMD-31044, EMD-31043, EMD-31046, and EMD-31045, respectively. All the other materials and data involved in this study will be available on request.

Conflict of interest

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41421-021-00264-3>.

Received: 7 January 2021 Accepted: 25 March 2021

Published online: 25 May 2021

References

1. Wang, X. et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. *Nat. Struct. Mol. Biol.* **19**, 424–429 (2012).
2. Leggiadro, R. J., Chwatsky, D. N. & Zucker, S. W. Echovirus 3 infection associated with anicteric hepatitis. *Am. J. Dis. Child.* **136**, 744–745 (1982).
3. Wang, K. et al. Structures of Echovirus 30 in complex with its receptors inform a rational prediction for enterovirus receptor usage. *Nat. Commun.* **11**, 4421 (2020).
4. Zhu, L. et al. Structures of Coxsackievirus A10 unveil the molecular mechanisms of receptor binding and viral uncoating. *Nat. Commun.* **9**, 4985 (2018).
5. Zhu, L. et al. Structure of human Aichi virus and implications for receptor binding. *Nat. Microbiol.* **1**, 16150 (2016).
6. Wang, K. et al. Serotype specific epitopes identified by neutralizing antibodies underpin immunogenic differences in Enterovirus B. *Nat. Commun.* **11**, 4419 (2020).
7. Wang, X. et al. Hepatitis A virus and the origins of picornaviruses. *Nature* **517**, 85–88 (2015).
8. Zhu, L. et al. Structure of Ljungan virus provides insight into genome packaging of this picornavirus. *Nat. Commun.* **6**, 8316 (2015).
9. Hu, D. et al. Structural and molecular basis for foot-and-mouth disease virus neutralization by two potent protective antibodies. *Protein Cell* <https://doi.org/10.1007/s13238-021-00828-9> (2020).
10. Wang, X. et al. Potent neutralization of hepatitis A virus reveals a receptor mimic mechanism and the receptor recognition site. *Proc. Natl Acad. Sci. USA* **114**, 770–775 (2017).
11. Zhao, X. et al. Human Neonatal Fc receptor is the cellular uncoating receptor for Enterovirus B. *Cell* **177**, 1553–1565.e16 (2019).